SCHEMBL2484739

SCHEMBL2484739

CCCC(O)[C@@H](N)CCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.48
LMNA P02545 2/20 0.48
SPHK1 Q9NYA1 2/20 0.48
GMNN O75496 1/20 0.48
POLB P06746 1/20 0.48
THPO P40225 1/20 0.48
MTOR P42345 1/20 0.48
BLM P54132 1/20 0.48
KDM4E B2RXH2 1/20 0.48
TP53 P04637 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAPT P10636 1/20 0.48
CETP P11597 1/20 0.48
HTT P42858 1/20 0.48
UBE2N P61088 1/20 0.48
CSNK1E P49674 1/20 0.37
TRPV1 Q8NER1 1/20 0.36
TRPA1 O75762 1/20 0.36
METAP1 P53582 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1719662 1.00 CYP2D6 (0.48) CYP2D6LMNASPHK1GMNNPOLB
Ammonia Solution, Strong SCHEMBL17695275 0.97 CYP2D6 (0.46) CYP2D6LMNASPHK1GMNNPOLB
Alcohol SCHEMBL2031858 0.92 CYP2D6 (0.48) CYP2D6LMNASPHK1GMNNPOLB
Monoethanolamine SCHEMBL2031859 0.88 CYP2D6 (0.45) CYP2D6LMNASPHK1GMNNPOLB
SCHEMBL7011294 0.87 CYP2D6 (0.59) CYP2D6LMNASPHK1GMNNPOLB
SCHEMBL1067106 0.87 CYP2D6 (0.48) CYP2D6LMNASPHK1GMNNPOLB
SCHEMBL14753951 0.87 CYP2D6 (0.48) CYP2D6LMNASPHK1GMNNPOLB
SCHEMBL14753958 0.86
SCHEMBL4208579 0.86
SCHEMBL3369535 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178686-B2 Process for preparing optically active aminopentane derivative, intermediate and process for preparing intermediate FUJIMOTO CO., LTD. (JP) 2012-05-15 US disclosed
EP-1905760-B1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE IN THE PROCESS AND PROCESS FOR PRODUCTION OF THE INTERMEDIATE FUJIMOTO CO LTD (JP) 2011-10-26 EP disclosed
US-20100324300-A1 PROCESS FOR PREPARING OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE AND PROCESS FOR PREPARING INTERMEDIATE YONEDA FUMIO 2010-12-23 US disclosed
US-7807840-B2 Process for preparing optically active aminopentane derivative, intermediate and process for preparing intermediate FUJIMOTO CO., LTD. (JP) 2010-10-05 US disclosed
US-20090124813-A1 Process for Preparing Optically Active Aminopentane Derivative, Intermediate and Process for Preparing Intermediate FUJIMOTO CO., LTD. (JP) 2009-05-14 US disclosed
EP-1905760-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE IN THE PROCESS AND PROCESS FOR PRODUCTION OF THE INTERMEDIATE Fujimoto Co., Ltd. (JP) 2008-04-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124813-A1 Process for Preparing Optically Active Aminopentane Derivative, Intermediate and Process for Preparing Intermediate API5, CASP5, BAD CYP2D6 232/4885LMNA 618/4885SPHK1 1987/4885
US-20100324300-A1 PROCESS FOR PREPARING OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE AND PROCESS FOR PREPARING INTERMEDIATE API5, CASP5, BAD CYP2D6 232/4885LMNA 618/4885SPHK1 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.